Showing results (21-30 of 67) with videos related to

Sort By:
Pageof 7
The Oncologist|July 29, 2011
Neoplastic meningitis from solid tumors: new diagnostic and therapeutic approachesGiuseppe Lombardi, Fable Zustovich, Patrizia Farina, et al.
Future Oncology (London, England)|February 18, 2016
Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinomaMarco Maruzzo, Umberto Basso, Alberto Diminutto, et al.
BJU International|May 20, 2008
Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trialOrazio Caffo, Teodoro Sava, Evi Comploj, et al.
Cancer|November 9, 2010
Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 studyGiuseppe Lombardi, Fable Zustovich, Fabio Farinati, et al.
Anticancer Research|May 1, 2007
A phase I study of cisplatin, temozolomide and thalidomide in patients with malignant brain tumorsFable Zustovich, Giuseppe Cartei, Renato Ceravolo, et al.
Open Access Journal of Urology|November 8, 2013
Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinomaFable Zustovich, Giuseppe Lombardi, Davide Pastorelli, et al.
Anticancer Research|December 29, 2010
Bevacizumab and glioblastomas, a single-centre experience: how disease history and characteristics may affect clinical outcomeFable Zustovich, Giuseppe Lombardi, Davide Pastorelli, et al.
Anticancer Research|July 31, 2013
Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II studyFable Zustovich, Lorenza Landi, Giuseppe Lombardi, et al.
Anti-Cancer Drugs|March 3, 2012
Cilengitide in bevacizumab-refractory high-grade glioma: two case reports and critical review of the literatureGiuseppe Lombardi, Fable Zustovich, Patrizia Farina, et al.
Anti-Cancer Drugs|December 3, 2009
Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinomaDavide Pastorelli, Fable Zustovich, Giovanni Faggioni, et al.
Pageof 7